Join the Heart Failure with Reduced Ejection Fraction group to help and get support from people like you.
Heart Failure with Reduced Ejection Fraction News (Page 3)
Weight Gain After Breast Cancer Development Tied to Heart Failure Risk
FRIDAY, Jan. 10, 2025 – For women with newly diagnosed invasive breast cancer (BC), weight gain is associated with an increased risk for heart failure, according to a research letter published...
Rheumatoid Arthritis Increases Risk for New Heart Failure
FRIDAY, Dec. 20, 2024 – Rheumatoid arthritis (RA) is associated with a higher rate of heart failure subtypes, according to a study published online Dec. 9 in Arthritis Care & Research. Yumeko...
PREVENT Equations Classify 15 Million at Elevated Risk for Heart Failure
MONDAY, Dec. 16, 2024 – The Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations classify 15.0 million U.S. adults as having an elevated risk for heart failure, according to a...
Gene Therapy Reverses Heart Failure in Pig Trials
TUESDAY, Dec. 10, 2024 – Failing hearts nearly returned to full function in laboratory pigs after they received an experimental gene therapy. New research shows the gene therapy didn’t just prevent h...
AHA: Variation Seen in Rates of SGLT2i Rx for Heart Failure, LVEF >40 Percent
TUESDAY, Nov. 26, 2024 – From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular...
Heart Failure With Preserved Ejection Fraction Underdiagnosed
MONDAY, Nov. 25, 2024 – Heart failure with preserved ejection fraction (HFpEF) is underdiagnosed in patients with severe secondary tricuspid regurgitation (STR) of undefined etiology (isolated STR),...
AHA: Tirzepatide Beneficial for Heart Failure With Preserved EF, Obesity
FRIDAY, Nov. 22, 2024 – For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart...
A-fib Plus Heart Failure a Dangerous Combo
WEDNESDAY, Nov. 20, 2024 – For the 4 in 10 patients with newly diagnosed heart failure who also have the heart rhythm disorder atrial fibrillation, the prognosis can be poor. "Atrial fibrillation...
Palliative Care Use Low in Patients With Heart Failure
WEDNESDAY, Nov. 13, 2024 – Use of palliative care for heart failure remains low in the United States, according to a study recently published online in the Journal of the American Heart Association. ...
Substantial Mortality Benefits Expected From Optimal Medication Use for HFrEF
WEDNESDAY, Oct. 16, 2024 – For individuals with heart failure with reduced ejection fraction (HFrEF), substantial mortality benefits would result from optimal use of guideline-directed medical...
About 6.7 Million Americans Older Than 20 Years Have Heart Failure
WEDNESDAY, Oct. 2, 2024 – About 6.7 million Americans older than age 20 years have heart failure, according to an updated report from the Heart Failure Society of America published online Sept. 24...
Event-Free Survival Extended With Long-Term Finerenone in Heart Failure
MONDAY, Sept. 30, 2024 – Long-term treatment with finerenone is estimated to extend event-free survival among people with heart failure with mildly reduced or preserved ejection fraction, according...
Endovascular Therapy Improves Left Ventricular Diastolic Function in HFpEF
FRIDAY, Sept. 20, 2024 – For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ventricular (LV) diastolic function, according to a...
FDA Approves Jardiance (empagliflozin) to Treat Adults Living with Heart Failure with Reduced Ejection Fraction
Ridgefield, Conn. and Indianapolis, August 18, 2021 – Jardiance (empagliflozin) 10 mg has been approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death plus h...
Entresto Granted Expanded Indication in Chronic Heart Failure by FDA
EAST HANOVER, N.J., Feb. 16, 2021 -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to red...